ArticleDermatology and therapy2025
Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis, a chronic inflammatory skin disease, affects approximately one million Canadians, with plaque psoriasis (PsO) being the most common subtype. While brodalumab has shown efficacy and safety in phase III clinical trials, Canadian real-world evidence remains limited. This retrospective cohort study aims to report on the real-world outcomes of Canadian patients with PsO who initiated treatment with brodalumab within the 4-year period following its approval by Health Canada.
methodsData from patients with PsO initiating brodalumab treatment in the Canadian patient support program between July 1, 2018 and June 30, 2022 were analyzed. The primary objective evaluated the proportion of patients achieving a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) at selected time windows. Secondary and exploratory objectives included assessing the 90% reduction in PASI score (PASI 90), changes from baseline in mean PASI, body surface area (BSA), and Dermatology Life Quality Index (DLQI) scores, as well as treatment persistence.
resultsA total of 2482 patients (58.5% male; mean age 51.0 years) were included, with over half being biologic-naïve (56.9%). In a subset of patients with baseline and at least one follow-up data, 66.1% and 53.2% achieved PASI 90 and PASI 100, respectively, within the first 3 months. These rates were sustained, with 68.1% and 52.2% achieving PASI 90 and PASI 100, respectively, beyond 24 months. Significant improvements from baseline were observed for PASI, BSA, and DLQI scores, and these improvements were maintained over time. Among all patients, the 1-year persistence rate was 73.4%.
conclusionsThis study provides valuable insights into the profile of patients treated with brodalumab in Canada. While the rapid and sustained skin clearance, as well as improvements in PASI, BSA, and DLQI scores, support the therapeutic benefits of brodalumab beyond clinical trials, further research on long-term effectiveness and safety is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.